SYROS PHARMACEUTICALS INC (SYRS) Stock Price, Quote, News and Overview
NASDAQ:SYRS - Nasdaq - US87184Q2066 - Common Stock - Currency: USD
SYRS Quote, Performance and Key Statistics
0.1743
0 (-0.85%)
The current stock price of SYRS is 0.1743 USD. In the past month the price decreased by -15.67%. In the past year, price decreased by -97.6%.
SYRS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SYRS
Company Profile
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The firm is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The firm is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Company Info
SYROS PHARMACEUTICALS INC
35 Cambridge Park Drive
Cambridge MASSACHUSETTS 02140 US
CEO: Nancy Simonian
Employees: 68
Company Website: https://syros.com/
Investor Relations: https://ir.syros.com/
Phone: 16177441340
SYROS PHARMACEUTICALS INC / SYRS FAQ
What is the stock price of SYROS PHARMACEUTICALS INC today?
The current stock price of SYRS is 0.1743 USD. The price decreased by -0.85% in the last trading session.
What is the ticker symbol for SYROS PHARMACEUTICALS INC stock?
The exchange symbol of SYROS PHARMACEUTICALS INC is SYRS and it is listed on the Nasdaq exchange.
On which exchange is SYRS stock listed?
SYRS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SYROS PHARMACEUTICALS INC stock?
9 analysts have analysed SYRS and the average price target is 10.71 USD. This implies a price increase of 6044.58% is expected in the next year compared to the current price of 0.1743. Check the SYROS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SYROS PHARMACEUTICALS INC worth?
SYROS PHARMACEUTICALS INC (SYRS) has a market capitalization of 4.68M USD. This makes SYRS a Nano Cap stock.
How many employees does SYROS PHARMACEUTICALS INC have?
SYROS PHARMACEUTICALS INC (SYRS) currently has 68 employees.
What are the support and resistance levels for SYROS PHARMACEUTICALS INC (SYRS) stock?
SYROS PHARMACEUTICALS INC (SYRS) has a resistance level at 0.18. Check the full technical report for a detailed analysis of SYRS support and resistance levels.
Is SYROS PHARMACEUTICALS INC (SYRS) expected to grow?
The Revenue of SYROS PHARMACEUTICALS INC (SYRS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SYRS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SYROS PHARMACEUTICALS INC (SYRS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SYRS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SYRS, evaluating the profitability, health, valuation and growth aspects
- SYROS PHARMACEUTICALS INC (SYRS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SYROS PHARMACEUTICALS INC (SYRS) Sales and EPS estimates to see what analysts future expectations are.
- SYROS PHARMACEUTICALS INC (SYRS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SYROS PHARMACEUTICALS INC (SYRS) Insider and Institutional Ownership to learn about the owners and their transactions.
- SYROS PHARMACEUTICALS INC (SYRS) Stock Chart to make your own analysis
- SYROS PHARMACEUTICALS INC (SYRS) Latest news and press-releases to stay up to date.
Does SYROS PHARMACEUTICALS INC (SYRS) stock pay dividends?
SYRS does not pay a dividend.
When does SYROS PHARMACEUTICALS INC (SYRS) report earnings?
SYROS PHARMACEUTICALS INC (SYRS) will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of SYROS PHARMACEUTICALS INC (SYRS)?
SYROS PHARMACEUTICALS INC (SYRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.03).
What is the Short Interest ratio of SYROS PHARMACEUTICALS INC (SYRS) stock?
The outstanding short interest for SYROS PHARMACEUTICALS INC (SYRS) is 2.74% of its float. Check the ownership tab for more information on the SYRS short interest.
SYRS Technical Analysis
SYRS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SYRS. SYRS may be in some trouble as it scores bad on both profitability and health.
SYRS Financial Highlights
Over the last trailing twelve months SYRS reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 19.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -115.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SYRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to SYRS. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 72.08% and a revenue growth -100% for SYRS